Vizimpro (dacomitinib) / SFJ Pharma, Pfizer - LARVOL DELTA

Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies. (PubMed, Exp Ther Med) - "Clinical outcomes varied by mutation subtype and EGFR-TKI regimen; relatively favorable progression-free survival (PFS) was observed with dacomitinib in L861Q and with afatinib- or dacomitinib-based treatment in selected S768I compound mutations. Exploratory Spearman analysis suggested that lower docking scores and more negative MM-GBSA ∆G_bind values were associated with longer PFS. These findings provide hypothesis-generating evidence that molecular simulation may help inform personalized EGFR-TKI selection for non-classical EGFR mutations, although validation in larger, consecutive and prospective multicenter cohorts is required."

Clinical data • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Second versusThird-Generation EGFR-TKIs as Frontline Treatment for EGFR-Mutant NSCLC: Interim Results From Korean EGFR Registry (IASLC-WCLC 2026) - "Among 1,954 total enrolled patients, we analyzed 1,198 patients with metastatic or recurrent disease treated with either 2G (n=701; afatinib [n=597] or dacomitinib [n=104]) or 3G TKIs (n=497; osimertinib [n=155] or lazertinib [n=342]) as frontline therapy. However, 3G EGFR-TKIs provide superior initial disease control (PFS and TTF) compared to 2G TKIs. Due to the relatively short follow-up period of the 3G group (16.9 months), more mature data are required to confirm long-term survival outcomes and the optimal treatment sequence in EGFR-mutant NSCLC."

IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • PD-L1

BRAINTOX: uremic toxins in chemotherapy response in the brain (EANO 2026) - "Then, U87MG cells were co-treated with p-cresyl sulfate or indoxyl sulfate and ten selected drugs in a drug screening platform (drugs: Temozolamide, Dacomitinib, Selinexor, Panobinostat, Ixazomib, AMG232, Bortezomib, Lazertinib, Temsirolimus, Carmilzomib). The uremic toxins p-cresyl sulfate and indoxyl sulfate were enriched in brain tumor tissue samples of IDH wt patients compared to IDH mut patients, validating the findings of the discovery cohort. IDH wt patients have higher levels of uremic toxins in the circulation compared to patients with IDH mutant adult-type diffuse gliomas and the toxins reach the tumor site. Further experiments shall elucidate the mechanism by which uremic toxins reach the tumor cells and whether they modulate drug responsiveness."

Brain Cancer • Diffuse Glioma • Glioblastoma • Glioma • Oncology • Solid Tumor

A Multicenter, Real-World Data Analysis of T-DXd Efficacy in Acquired HER2 Alterations After Resistance to Osimertinib (IASLC-WCLC 2026) - "Of the 9 patients treated with HER2-directed therapy, 5 received T-DXd plus osimertinib, 2 received T-DXd monotherapy, and 2 received dacomitinib plus osimertinib. Only one grade 3 treatment-related adverse event (20.0%) was observed in the T-DXd plus osimertinib group. Conclusions : In conclusion, T-DXd-based therapy may represent a potential strategy to overcome acquired HER2 alterations after osimertinib resistance."

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

Impact of Cumulative Smoking Dose on EGFR-TKIs Outcomes in Advanced EGFR-Mutant NSCLC (IASLC-WCLC 2026) - "First-generation TKIs (gefitinib/erlotinib), second-generation TKIs (afatinib/dacomitinib), and third-generation TKIs (osimertinib/lazertinib) were administered in 13.4%, 50.7%, and 35.9% of patients. Conclusions : Higher cumulative smoking dose was associated with inferior clinical outcomes in advanced EGFR-mutant NSCLC treated with EGFR-TKIs. The detrimental effect was most pronounced in heavy smokers treated with osimertinib while Lazertinib showed good response suggesting that cumulative smoking dose may serve as a useful clinical stratification factor and a rationale for treatment intensification in selected patients."

Metastases • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

INVESTIGATION OF THE ANTICANCER EFFECTS OF DACOMITINIB AND CURCUMIN ON COLORECTAL CANCER USING IN VITRO AND IN SILICO APPROACHES (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Colorectal Cancer • Oncology • Solid Tumor

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study. (PubMed, ESMO Open) - "Dacomitinib has outstanding intracranial efficacy in patients with EGFR-mutant NSCLC with brain metastases."

Journal • P2 data • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, J Egypt Natl Canc Inst) - "While several EGFR-TKIs improved efficacy over first-generation agents, no single treatment was clearly superior across all efficacy and safety outcomes. Osimertinib showed consistent efficacy, while its safety advantage became evident in the sensitivity analysis excluding FLAURA China."

Clinical • Journal • Retrospective data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Dacomitinib in Advanced NSCLC With Uncommon EGFR Mutations: A Biomarker Analysis of a Phase II Study (IASLC-WCLC 2026) - "Conclusions : Dacomitinib has high anti-tumor activity and manageable toxicity in advanced NSCLC patients with uncommon EGFR mutations. Ct-DNA is a useful biomarker for predicting treatment efficacy and identifying drug resistance mechanisms."

Biomarker • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • HER-2 • MET

Pulsed Azithromycin for the Treatment of Dacomitinib Induced Skin Toxicity in Patient with Tetracycline Intolerance - A Case Report. (PubMed, Clin Exp Dermatol) - "Azithromycin was administered using various dosing strategies, and we found 500 mg every other day might be the most effective regimen for treating EGFR-TKI-induced acneiform rash. However, this approach appeared to be less effective in managing paronychia."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Drug-induced paronychia: a disproportionality and time-to-onset pharmacovigilance study using FAERS and JADER. (PubMed, Cutan Ocul Toxicol) - "The ten drugs with the strongest disproportionality signals (ranked by ROR) were Dacomitinib [ROR 374.77; 95% CI 276.31-508.31], Selumetinib [304.66; 228.55-406.10], Afatinib [296.98; 264.27-333.74], Panitumumab [204.37; 183.10-228.11], Amivantamab [167.61; 124.71-225.26], Necitumumab [151.38; 67.14-341.35], Mobocertinib [117.03; 71.21-192.34], Erdafitinib [59.36; 33.57-104.99], Lapatinib [48.09; 39.71-58.24], and Gefitinib [47.28; 37.09-60.27]...Time-to-onset analysis of 30 drugs with valid TTO data revealed that median onset times ranged from 4 days (Necitumumab) to 575.5 days (Alendronate), with several of the most frequently reported EGFR and MEK inhibitors exhibiting an early-failure pattern (Weibull β < 1), supporting concentrated monitoring during the first weeks of therapy...These findings, derived from spontaneous reporting data, indicate associations rather than causal risk and require further clinical and epidemiologic evaluation. The signals identified may..."

Adverse events • Journal • Oncology • Pain

Integrated machine learning and molecular dynamics-driven multi-target virtual screening of FDA-approved drugs for drug repurposing in breast cancer. (PubMed, In Silico Pharmacol) - "Ponatinib emerged as the top-ranked computational candidate (mean: - 10.07 kcal/mol), followed by Regorafenib (- 9.64), Sorafenib (- 9.46), and Entrectinib (- 9.45), while non-oncology drugs including antrafenine, betrixaban, and maraviroc demonstrated novel multi-target binding profiles...MM-GBSA calculations revealed a binding hierarchy concordant with docking scores (R2 = 0.92): Ponatinib-VEGFR2 (ΔGbind = - 42.38 kcal/mol) > Entrectinib-CDK6 (- 38.56) > Ponatinib-EGFR (- 33.24) > Entrectinib-HER2 (- 28.47) > Dacomitinib-HDAC3 (- 24.63 kcal/mol)...As the present study is entirely computational, the identified compounds should be regarded as hypothesis generating leads requiring experimental validation through in vitro kinase and HDAC3 inhibition assays, cell based studies, and target engagement confirmation before any translational conclusions can be drawn. The online version contains supplementary material available at..."

FDA event • Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK6 • EGFR • HDAC3 • HER-2 • KDR

HPD is a copper-binding protein that interacts with DLAT to promote colorectal cancer cuproptosis under copper stress. (PubMed, Cell Rep) - "Furthermore, we identify Dacomitinib as an HPD-targeting cuproptosis inducer, which triggers CRC cuproptosis by enhancing the interaction between HPD and DLAT...In summary, our findings reveal that HPD, as a copper-binding protein, facilitates cuproptosis in cancer cells through its moonlighting function. This mechanism represents a therapeutic target for enhancing cuproptosis."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CDC37 • DLAT • HSP90AA1

Novel therapeutic targets in drug-resistant BRAFV600E paediatric high-grade glioma (ISPNO 2026) - "In vitro cytotoxicity assays confirmed the resistant nature of BRAF inhibitor-resistant, MEK inhibitor-resistant and BRAF+MEK inhibitor-resistant BRAFV600E pHGG cultures, derived through chronic exposure of a BRAFV600E patient-derived culture to vemurafenib (BRAFi), trametinib (MEKi) or a combination of both drugs, respectively. This resistance was further validated in vivo, where animals orthotopically xenografted with vemurafenib-resistant cells demonstrated significantly reduced survival following BRAF inhibition (dabrafenib) treatment compared to those bearing matched parental tumours.All three resistant cell lines spontaneously transformed from a spheroid phenotype to adherent growth; proteomics pathway analysis correspondingly identified enrichment of extracellular matrix and cytoskeletal pathways...Erdafitinib (FGFRi) displayed potent synergistic activity when combined with vemurafenib against vemurafenib-resistant BRAFV600E pHGG cells and parental cells in vitro,..."

Brain Cancer • Glioma • High Grade Glioma • Pediatrics • Solid Tumor • EGFR • FGFR • NTRK2

Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis. (PubMed, Ther Adv Med Oncol) - "This study suggests that a 30-mg starting dose of dacomitinib may provide similar efficacy with improved tolerability compared with 45 mg. Prospective noninferiority studies are warranted to confirm these findings."

Journal • Retrospective data • Anorexia • Dental Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Stomatitis • EGFR

Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study. (PubMed, Transl Lung Cancer Res) - "Grade ≥3 treatment-related adverse events (TRAEs) occurred in 14.3% (n=6) of patients, with no grade 5 events. Dacomitinib is a promising, well-tolerated option for EGFR 21-L858R-mutated NSCLC patients with third-generation EGFR-TKI resistance, warranting prospective clinical trials for validation."

Journal • Preclinical • Real-world evidence • Retrospective data • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Cardiovascular toxicity across epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutated non–small cell lung cancer: A population-based retrospective cohort study. (ASCO 2026) - "Patients were classified into three groups: first-generation (1G) EGFR TKIs (gefitinib or erlotinib), second-generation (2G) TKIs (afatinib or dacomitinib), and third-generation (3G) TKI sequence (initial first- or second-generation TKI followed by a switched to osimertinib). The long-term risk of CVD associated with sustained treatment with 1G EGFR TKIs appears comparable to the risk observed among patients who started with 1G or 2G and switched to 3G EGFR TKI sequence. As long-term survivors with EGFR mutant NSCLC increases in number, ongoing surveillance for cardiotoxicity and proactive risk mitigation are essential."

Retrospective data • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Dyslipidemia • Heart Failure • Hypertension • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer. (PubMed, Clin Med Insights Oncol) - "Initial low-dose dacomitinib demonstrated promising efficacy with an improved safety profile in patients with EGFR exon 21-mutated NSCLC. These findings support the feasibility of a dose-optimization strategy, although further prospective studies are warranted."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

The economic and clinical impact of lung cancer patient support programs (LC-PSP) using real-world (RW) clinical outcomes. (ASCO 2026) - "67% of LC-PSP drugs provided were targeted oral inhibitors for actionable alterations [ALK (crizotinib, alectinib, lorlatinib), EGFR (afatinib, dacomitinib, osimertinib), RET (selpercatinib), and ROS1 (crizotinib)], 17% immune checkpoint inhibitors (neoadjuvant nivolumab), 12% other monoclonal antibody (amivantamab), and 3% T-cell engagers (tarlatamab). This RW study shows that LC-PSPs provide substantial financial value and critically bridge the > 2-yr gap between HC approval and provincial funding for novel lung cancer therapies. Our findings reflect meaningful patient benefit through inferred survival gains and improved quality of life from extended disease control and underscore the need to reform regulatory processes to ensure equitable access to effective new therapies. Opportunities, including navigation support, to strengthen interim access through efficient identification of eligible patients and streamlining PSP applications will further enhance access to..."

Clinical • Clinical data • Real-world • Real-world evidence • Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1

Mechanistic Study of the Antidepressant Agomelatine in Modulating STING Activity During the Pathogenesis of Systemic Lupus Erythematosus (EULAR 2026) - "Peritoneal macrophages (PEMs) were were stimulated with various stimuli, including lipopolysaccharide (LPS), interferon-stimulatory DNA (ISD), herpes simplex virus (HSV), cyclic GMP-AMP (cGAMP), ABT-737 + QVD-OPh, at different time points (0 h, 3 h, 6 h)...RT-qPCR results showed that the EGFR inhibitor Dacomitinib attenuated the suppressive effect of AGO on IFN-related gene expression in ISD/cGAMP-stimulated macrophages...Behavioral tests, including the tail suspension test (TST), forced swim test (FST), and open field test (OFT), demonstrated that AGO significantly ameliorated depression-like behaviors in lupus model mice. Conclusions This study elucidates the molecular mechanism by which the antidepressant AGO modulates STING activity and the subsequent production of IFN-I, thereby laying a theoretical foundation of novel therapeutics for SLE."

Cardiovascular • CNS Disorders • Depression • Herpes Simplex • Immunology • Inflammatory Arthritis • Lupus • Mood Disorders • Sleep Disorder • Systemic Lupus Erythematosus • CCL2 • CXCL1 • CXCL10 • CXCL12 • CXCL5 • CXCL9 • IFNB1 • IRF7 • MX1 • STING

A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer. (clinicaltrials.gov) - P=N/A | N=29 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Sep 2025 | Trial primary completion date: Dec 2026 ➔ Sep 2025

HEOR • Real-world evidence • Trial completion • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Network toxicology and bioinformatics reveal potential molecular links between cadmium exposure and pancreatic cancer. (PubMed, BMC Pharmacol Toxicol) - "This study reveals that Cd may promote the malignant progression of PC by regulating ECM remodeling through key genes such as FN1. Dacomitinib shows promise as an FN1-associated therapy, offering new insights for the precise prevention and treatment of Cd-associated PC."

Journal • Oncology • Pancreatic Cancer • Solid Tumor • COL3A1 • COL5A1 • FN1 • TIMP1

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. (PubMed, Mol Oncol) - "Combination studies revealed that W1B acts synergistically with the EGFR inhibitor dacomitinib, effectively overcoming compensatory activation of parallel pathways...The in vivo studies on Danio rerio have shown a good safety profile, as well as strong antitumor potential of the tested compound. Therefore, these findings establish W1B as a promising derivative for the development of next-generation dual IGF1R/EGFR inhibitors in GBM."

Journal • Brain Cancer • Diabetes • Glioblastoma • Oncology • Solid Tumor • IR

Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report. (PubMed, Front Oncol) - "The patient initially received pemetrexed plus carboplatin chemotherapy. The treatment efficacy was evaluated as a partial response (PR), with manageable adverse events including skin rash and paronychia. Dacomitinib may provide sustained clinical benefit and an acceptable safety profile in lung adenocarcinoma patients with L747P mutation and bone metastases."

Journal • Dermatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Over 200! The largest BaF3-EGFR engineering cell lines collection, a useful platform for novel drug discovery (AACR 2025) - "Recognizing EGFR as a driver gene has accelerated the development of targeted anticancer therapies, such as monoclonal anti-EGFR antibodies (cetuximab, panitumumab) and small molecule receptor tyrosine kinase inhibitors (TKIs). The first generation of EGFR TKIs, like gefitinib and erlotinib, specifically target mutations such as L858R and exon 19 deletions. To address resistance to these early inhibitors, second-generation EGFR TKIs (afatinib, dacomitinib) were developed...Osimertinib, a third-generation TKI, was approved for use in EGFR-mutated NSCLC following the failure of first- and second-generation TKIs, although the EGFR C797S mutation limits its effectiveness. Fourth-generation EGFR TKIs, including BLU-945 and BBT-176, are under clinical evaluation but are not yet approved.We have created more than 200 Ba/F3-EGFR engineered cell lines, making this the largest in vitro and in vivo platform for drug discovery with the widest range of mutant cells. These cell lines..."

Preclinical • Brain Cancer • Breast Cancer • Colon Cancer • Colorectal Cancer • Head and Neck Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • EGFR • EPGN • ERBB3 • ERBB4 • HBEGF • HER-2 • TGFA